Purpose The aim of this study was to assess the safety profiles of two biosimilar medicines
(rituximab and trastuzumab) in the treatment of cancer patients within a Portuguese …

Aim To compare the efficacy and safety of rituximab biosimilars to reference rituximab in
patients with cancer. Data Sources A systematic review and meta‐analysis was conducted …

OBJECTIVES: Limited data exist on the adoption of rituximab biosimilars vs the reference
product by indication. Available data from real-world studies comparing rituximab biosimilar …

Purpose The aim of this study was to analyse the suspected adverse reactions associated
with rituximab or trastuzumab reported to the Spanish Pharmacovigilance System. Methods …

Simple Summary Nowadays, biosimilar drugs are numerous and widely used in many
clinical fields, including oncology. However, skepticism remains towards these products …

Aim: To describe treatment patterns and patient and provider characteristics associated with
the recently introduced biosimilar rituximab-pvvr. Methods: This retrospective analysis …

Background Biosimilar products of rituximab came to market in 2017. French
pharmacovigilance centers have highlighted an excess of case reports of severe …

Background: Rituximab is a chimeric monoclonal antibody which targets CD20 and is used
for treatment of CD20 associated oncologic/hematologic conditions. Murine-derived variable …

Biosimilars have the potential to broaden patient access to biologics and provide cost
savings for health care systems. During the development of a biosimilar, data that directly …

Purpose The purpose of this study was to evaluate the in-use physicochemical and
biological stability of the Sandoz rituximab biosimilar, marketed under the trade names …